LAG3 (CD223), a strongly up-regulated gene in NCM in both the H+C- and H+C+ conditions, is involved in antigen presentation by dendritic cells to T lymphocytes and is a checkpoint inhibitor target for investigative cancer and immunotherapy drugs [42, 43], while also being implicated in atherosclerotic disease [44]. Here, LAG3 is linked to cancer.